

Special Issue

Updates on Epigenetics of Brain Tumor

Message from the Guest Editor

Primary malignant brain tumors can affect people of any age, including children, and are usually highly aggressive as well as heterogeneous cancers. Epigenetic alterations are a well-established hallmark of these cancers, though there is still a critical need to gain a deeper understanding of their specific roles during tumorigenesis. This Special Issue, dedicated to the epigenetics of malignant brain tumors, with a special focus on glioblastoma multiforme, will highlight the causes and functional consequences of a dysregulated epigenetic landscape in these frequently fatal cancers, covering both basic and more clinical aspects. Original experimental and clinical studies, as well as reviews, studying the plethora of altered epigenetic mechanisms in cancerous brain tumors are invited. Finally, how epigenetic players could represent clinical targets, in addition to how their modulation could inform novel therapeutic strategies, and future challenges to overcome for spurring their translation into clinical oncology will also be discussed.

Guest Editor

Dr. Virginia López Martínez

1. University Institute of Oncology of Asturias (IUOPA), University of Oviedo, 33006 Oviedo, Spain
2. Health Research Institute of Asturias (ISPA), 33011 Oviedo, Spain

Deadline for manuscript submissions

closed (30 November 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/162424

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)